Anthony Walsh

Anthony Walsh serves as Strategic Advisor at Reverb Therapeutics where he aids with areas such as pipeline development and operations. Anthony concurrently serves as CEO and co-founder of Synkentro Therapeutics, which is focused on developing novel antibodies for autoimmune diseases. He previously spent more than a decade in biotech investing at venture capital firms including RA Capital and Mission BioCapital (where he served as partner).

He holds a BA in Biochemistry from Trinity College, Dublin, and a Ph.D. in Biophysics from Oxford University.

His doctoral research investigated the biological applications of DNA cages, including potential uses in the targeted delivery of macromolecules into living cells.